Amneal Pharmaceuticals has voluntarily recalled several lots of Metformin Hydrochloride Extended-Release Tablets (500 mg and 750 mg) due to the detection of N-Nitrosodimethylamine (NDMA). NDMA is a substance that is classified as a probable human carcinogen. This recall affects approximately 192 units distributed nationwide across various bottle sizes including 90-count, 100-count, 500-count, and 1000-count bottles, as well as bulk containers.
Testing revealed that certain lots contained NDMA levels above the acceptable daily intake limit. Long-term exposure to levels of NDMA above these limits may increase the risk of developing cancer.
Contact healthcare provider and return product for refund.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.